Page last updated: 2024-11-02

oxonic acid and Hilar Cholangiocarcinoma

oxonic acid has been researched along with Hilar Cholangiocarcinoma in 2 studies

Oxonic Acid: Antagonist of urate oxidase.

Research Excerpts

ExcerptRelevanceReference
"Although the combination of cisplatin and gemcitabine (GEM) is considered the standard first-line chemotherapy against unresectable hilar cholangiocarcinoma (HC), its efficacy is discouraging."9.22Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial. ( Guan, J; Li, H; Tong, DN; Zhang, ZY; Zhou, GW; Zhou, ZQ, 2016)
"Although the combination of cisplatin and gemcitabine (GEM) is considered the standard first-line chemotherapy against unresectable hilar cholangiocarcinoma (HC), its efficacy is discouraging."5.22Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial. ( Guan, J; Li, H; Tong, DN; Zhang, ZY; Zhou, GW; Zhou, ZQ, 2016)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Hosoda, K1
Fukushima, K1
Shimizu, A1
Motoyama, H1
Kubota, K1
Notake, T1
Sugenoya, S1
Hayashi, H1
Yasukawa, K1
Kobayashi, R1
Soejima, Y1
Li, H1
Zhang, ZY1
Zhou, ZQ1
Guan, J1
Tong, DN1
Zhou, GW1

Trials

1 trial available for oxonic acid and Hilar Cholangiocarcinoma

ArticleYear
Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial.
    Oncotarget, 2016, May-03, Volume: 7, Issue:18

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; CA-19-9 Antigen; D

2016

Other Studies

1 other study available for oxonic acid and Hilar Cholangiocarcinoma

ArticleYear
Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
    Oncology, 2021, Volume: 99, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2021